Compare Lupin with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs CADILA HEALTHCARE - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN CADILA HEALTHCARE LUPIN/
CADILA HEALTHCARE
 
P/E (TTM) x 41.5 29.7 139.8% View Chart
P/BV x 3.8 5.2 73.3% View Chart
Dividend Yield % 0.6 0.7 85.6%  

Financials

 LUPIN   CADILA HEALTHCARE
EQUITY SHARE DATA
    LUPIN
Mar-20
CADILA HEALTHCARE
Mar-20
LUPIN/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs882352 250.4%   
Low Rs505207 244.6%   
Sales per share (Unadj.) Rs339.4139.2 243.8%  
Earnings per share (Unadj.) Rs-5.911.8 -50.5%  
Cash flow per share (Unadj.) Rs15.518.6 83.3%  
Dividends per share (Unadj.) Rs6.003.50 171.4%  
Dividend yield (eoy) %0.91.3 69.1%  
Book value per share (Unadj.) Rs276.7101.4 273.1%  
Shares outstanding (eoy) m453.001,023.74 44.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.02.0 101.8%   
Avg P/E ratio x-116.623.7 -491.1%  
P/CF ratio (eoy) x44.815.0 297.9%  
Price / Book Value ratio x2.52.8 90.9%  
Dividend payout %-100.929.8 -339.1%   
Avg Mkt Cap Rs m314,201286,033 109.8%   
No. of employees `00018.313.4 136.5%   
Total wages/salary Rs m29,86824,145 123.7%   
Avg. sales/employee Rs Th8,400.610,632.7 79.0%   
Avg. wages/employee Rs Th1,632.01,801.2 90.6%   
Avg. net profit/employee Rs Th-147.2898.5 -16.4%   
INCOME DATA
Net Sales Rs m153,748142,531 107.9%  
Other income Rs m4,8381,139 424.7%   
Total revenues Rs m158,585143,670 110.4%   
Gross profit Rs m24,84924,198 102.7%  
Depreciation Rs m9,7026,965 139.3%   
Interest Rs m3,6303,418 106.2%   
Profit before tax Rs m16,35514,954 109.4%   
Minority Interest Rs m4288 1.4%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5713,198 361.8%   
Profit after tax Rs m-2,69412,044 -22.4%  
Gross profit margin %16.217.0 95.2%  
Effective tax rate %70.821.4 330.8%   
Net profit margin %-1.88.5 -20.7%  
BALANCE SHEET DATA
Current assets Rs m154,13287,154 176.9%   
Current liabilities Rs m92,25282,694 111.6%   
Net working cap to sales %40.23.1 1,286.2%  
Current ratio x1.71.1 158.5%  
Inventory Days Days8271 114.9%  
Debtors Days Days12994 137.8%  
Net fixed assets Rs m89,082133,236 66.9%   
Share capital Rs m9061,024 88.5%   
"Free" reserves Rs m124,461102,733 121.1%   
Net worth Rs m125,367103,757 120.8%   
Long term debt Rs m17,93332,146 55.8%   
Total assets Rs m249,839236,866 105.5%  
Interest coverage x5.55.4 102.4%   
Debt to equity ratio x0.10.3 46.2%  
Sales to assets ratio x0.60.6 102.3%   
Return on assets %0.46.5 5.7%  
Return on equity %-2.111.6 -18.5%  
Return on capital %8.713.7 63.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45052,752 97.5%   
Fx outflow Rs m19,47014,504 134.2%   
Net fx Rs m31,98038,248 83.6%   
CASH FLOW
From Operations Rs m14,68825,054 58.6%  
From Investments Rs m11,070-10,123 -109.4%  
From Financial Activity Rs m-8,906-10,942 81.4%  
Net Cashflow Rs m16,8533,989 422.5%  

Share Holding

Indian Promoters % 46.6 74.8 62.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 8.3 136.1%  
FIIs % 31.9 5.9 540.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 11.0 91.8%  
Shareholders   98,259 44,069 223.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   DR. DATSONS LABS  BIOCON   FULFORD INDIA  NATCO PHARMA  DIVIS LABORATORIES  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 16, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS